Quoin Pharmaceuticals Partners with AI to Revolutionize Biotechnology Research and Innovation

Strategic AI Partnership Set to Transform Swiss Biotechnology Landscape

Swiss Rockets AG, a Basel-based biotechnology incubator and accelerator, announces a strategic partnership with Squirro AG, a leading Swiss enterprise AI company, to revolutionize its research and innovation capabilities through advanced artificial intelligence. This collaboration, unveiled on October 23, 2025, aims to integrate Squirro's Generative AI Platform into Swiss Rockets' digital knowledge ecosystem. The focus of this partnership is to enhance innovation, streamline research processes, and improve decision-making across the company’s biotech portfolio.

By embedding Squirro’s AI and Knowledge Graph technologies within its secure infrastructure, Swiss Rockets is set to create a unified intelligence layer across various knowledge domains. This development signifies a substantial leap toward an AI-empowered operational framework, enabling the organization to process and synthesize information from internal documents, research archives, and external public sources efficiently. Sergey Kravchenko, Executive Chairman of Squirro, notes that such AI capabilities can empower organizations to optimize resource use while improving productivity. Dr. Vladimir Cmiljanovic, Founder and CEO of Swiss Rockets, emphasizes the initiative's goal of transforming the company into a fully AI-driven entity, enhancing both knowledge management and decision-making processes.

The partnership marks the beginning of the Swiss Rockets AI Assistant rollout, which will further include use cases focused on research intelligence and knowledge management. This roadmap is designed to lay the foundation for a comprehensive AI transformation. Both companies are committed to ensuring that their AI implementations adhere to stringent security protocols and regulatory compliance, including GDPR, HIPAA, and the EU AI Act, with all systems operating from Swiss Rockets' ISO 27001-certified Swiss cloud environment. This collaboration not only stands to enhance Swiss Rockets’ operational capabilities but also sets a benchmark for innovation within the life sciences sector.

In related industry news, INOVIO (NASDAQ: INO), a biotechnology firm specializing in DNA medicines for HPV-associated diseases, cancer, and infectious diseases, is scheduled to participate in the upcoming Stephens Biotechnology Virtual Fireside Chat Conference on November 4, 2025. This engagement underscores INOVIO's efforts to strengthen investor relationships and promote its pioneering work in the biotechnology realm.

As the biotechnology sector continues to evolve, strategic partnerships and technological advancements like those seen between Swiss Rockets and Squirro signal an exciting era of innovation, promising significant improvements in research and operational efficiencies.